Regulatory filing 📈 Stocks 🌍 United States

InfuSystem Holdings Reaffirms FY2025 Results With $143.4M Revenue

InfuSystem Holdings reaffirmed its FY2025 financial results, highlighting $143.4 million in net revenue and $31.5 million in Adjusted EBITDA, while maintaining a long-term Adjusted EBITDA margin target of 22%-25%.

📅 November 9, 2026 🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: INFU → 2/10 (70% confidence).

📊 Affected Assets (1)

INFU

Neutral 🤖 70%

📅 Short-term 🌍 US · Explicit

The filing is an investor presentation restating already-completed FY2025 results: net revenue $143.4M (+6% YoY), Adjusted EBITDA $31.5M (+25%), margin 21.9%, operating cash flow $24.4M and $58.2M liquidity. No new guidance, contracts or events are announced, so there is little incremental information to reprice the shares.

Catalysts

• Restated FY2025 metrics: net revenue $143.4M (+6% YoY), Adjusted EBITDA $31.5M (+25% YoY)
• $58.2M liquidity and long-term Adjusted EBITDA margin target of 22%-25%

Risk Factors

• Presentation contains only forward-looking statements with no new quantified outlook or binding commitments

🧭 Full analysis of these assets

🎯 Key Takeaways

FY2025 net revenue reached $143.4 million, a 6% increase year-over-year.
Adjusted EBITDA for FY2025 was $31.5 million, reflecting a 25% year-over-year growth.
The company reported $58.2 million in liquidity as of the most recent completed fiscal year.
InfuSystem maintains a long-term Adjusted EBITDA margin target of 22%-25%.
Wound care treatment revenue grew 103% year-over-year in 2025.

📝 Executive Summary

InfuSystem Holdings released an investor presentation on November 9, 2026, restating its fiscal year 2025 financial performance. The company reported net revenue of $143.4 million, representing a 6% year-over-year increase, and an Adjusted EBITDA of $31.5 million, up 25% from the prior year.

❓ FAQ

Did InfuSystem report new results in this filing?

No, it repeats FY2025 figures already completed: revenue of $143.4M and Adjusted EBITDA of $31.5M, without new guidance.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article